Natco Pharma Limited has informed the Exchange regarding a press release dated April 10, 2021, titled "NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA ��) ANDA in the US market".
Press Release Apr 10 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release announcing the tentative approval of its Ibrutinib tablets by the U.S. Food and Drug Administration. The approval is for multiple strengths of the tablets, which are a generic version of IMBRUVICA. NATCO expects to have a period of sole generic marketing exclusivity upon launch. The press release highlights significant sales figures for IMBRUVICA in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from NATCO Pharma
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
- Press Release Mar 15 2021
- Press Release Mar 08 2021
- NATCO Pharma launches Brivaracetam tablets, in India, for treatment of epilepsy
- Press Release Feb 26 2021
Later from NATCO Pharma
- NATCO Pharma receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA) ANDA in the US market
- Press Release Apr 26 2021
- Press Release May 03 2021
- Press Release May 17 2021
- Press Release May 21 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma